Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

547.36 -0.38 (-0.07%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 456,417
Open 547.75
Bid (Size) 545.45 (1)
Ask (Size) 554.94 (1)
Prev. Close 547.74
Today's Range 546.61 - 555.00
52wk Range 476.49 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield 0.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Beaten-Down Stocks to Buy and Hold
Via The Motley Fool
Topics Death
REGENERON PHARMACEUTICALS (NASDAQ:REGN) - A Potential Undervalued Biotech Stock
REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers strong profitability, financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector. 
Via Chartmill

Performance

YTD
-23.5%
-23.5%
1 Month
+12.9%
+12.9%
3 Month
-6.0%
-6.0%
6 Month
-23.8%
-23.8%
1 Year
-47.1%
-47.1%

More News

Read More
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
Via Benzinga
Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps
Via Stocktwits
Topics Death
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For July 01
Via Benzinga
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Via MarketBeat
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
1 Profitable Stock for Long-Term Investors and 2 to Question
Via StockStory
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Via Benzinga
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
Via StockStory
Topics Artificial Intelligence
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
Via Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
Via Stocktwits
Topics Supply Chain
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss
Via Stocktwits
Topics Death
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Via Benzinga
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
Via The Motley Fool
Topics Stocks
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
From 23andMe, Inc.
Via GlobeNewswire
These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025
Via The Motley Fool
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Via The Motley Fool
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Via Benzinga

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 547.36
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 07/03/25 01:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 50.24B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 50B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.